1,167 results on '"Seto, Wai-Kay"'
Search Results
2. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD
3. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
4. Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium
5. Pilot model of hepatitis C virus micro-elimination in high-risk populations in Hong Kong: Barriers and facilitators
6. Application of a deep learning algorithm for the diagnosis of HCC
7. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B
8. Dual-tracer PET/CT in the management of hepatocellular carcinoma
9. Dual-Attention Enhanced BDense-UNet for Liver Lesion Segmentation
10. Prevalence and risk factors for impaired renal function among Asian patients with nonalcoholic fatty liver disease
11. Immediate postpartum cessation of tenofovir did not increase risk of virological or clinical relapse in highly viremic pregnant mothers with chronic hepatitis B infection
12. Virological response to nucleos(t)ide analogues treatment in chronic hepatitis B patients is associated with Bacteroides-dominant gut microbiome
13. Geographic disparities in access to liver transplant for advanced cirrhosis: Time to ring the alarm!
14. Predictors of hepatic flares after nucleos(t)ide analogue cessation – Results of a global cohort study (RETRACT-B study)
15. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy
16. Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study
17. High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter
18. Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy
19. Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers
20. Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies
21. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
22. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
23. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study
24. Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium
25. Shared-care models are highly effective and cost-effective for managing chronic hepatitis B in China: reinterpreting the primary care and specialty divide
26. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
27. Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection
28. Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection
29. A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays
30. New strategies for the treatment of chronic hepatitis B
31. Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma
32. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
33. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)
34. Cigarette Smoking Is Associated With Lower Chance of Hepatitis B Surface Antigen Seroclearance and Altered Host Immunity.
35. Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes.
36. Effect of metabolic dysfunction‐associated steatotic liver disease on BNT162b2 immunogenicity against the severe acute respiratory syndrome coronavirus 2 omicron variant.
37. Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
38. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)
39. A randomized controlled trial enhancing viral hepatitis testing in primary care via digital crowdsourced intervention
40. LBP-019 Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B
41. FRI-088 Patterns and predictors of postacute discharge location other than home in a global cohort of 3, 678 patients hospitalized with cirrhosis
42. OS-032 Long-term hepatitis B surface antigen response after finite treatment with siRNAs ARC-520 or JNJ-3989
43. WED-373-YI Epidemiological data and clinical profiles of hepatitis B surface antigen levels in chronic hepatitis B: implications for novel drug development
44. SAT-314 Impact of hepatic steatosis on risk of acute liver injury among people with chronic hepatitis B and SARS-CoV-2 infection
45. FRI-490-YI Intratumoural microbiome alterations predict postoperative recurrence and mortality in hepatocellular carcinoma after hepatic resection
46. SAT-392 Perturbed pathways of lipid metabolism in patients with chronic hepatitis B infection after cessation of long term nucleos (t)ide analogue
47. FRI-388 Clinically significant liver stiffness decrease, as defined by the Baveno VII consensus, is associated with improved long-term prognosis in chronic hepatitis B patients with compensated advanced chronic liver disease
48. SAT-375 Proteomic analysis of plasma exosomes: a novel method to identify potential therapeutic targets for chronic hepatitis B
49. Hepatocellular carcinoma: Advances in systemic therapies
50. Functional cure of CHB encounters resmetirom
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.